One morning email with every new regulatory, quality & compliance role your alert matches.
Showing 1–12 of 26 articles
The EU's Health Technology Assessment Regulation adds a joint clinical assessment to the approval pathway. Here's what it means for regulatory affairs careers.
The EU's Falsified Medicines Directive safety features reshaped packaging and submission work. Here's what regulatory affairs teams need to know.
FDORA strengthened FDA's accelerated approval authorities around confirmatory trials and withdrawal. What it means for regulatory affairs work and strategy.
EMA's PRIME scheme compresses development timelines and turns scientific advice into an ongoing relationship. What that means for regulatory affairs teams.
The MHRA's Innovative Licensing and Access Pathway is pulling UK regulatory engagement earlier into development. What ILAP involves and what it means for regulatory affairs teams.
FDORA's Diversity Action Plan requirement adds a new, enforceable document to clinical trial submissions. Here is what it asks for and what it means for day-to-day regulatory work.
Japan's Sakigake designation and its distinct regenerative medicine pathway are changing how companies staff regulatory affairs for the Japanese market.
How FDA's FSMA 204 Food Traceability Rule works, where its compliance timeline stands, and the new regulatory affairs roles it's creating in food safety.
How the EU Clinical Trials Regulation and the CTIS portal changed clinical trial submissions in Europe, and what it means for regulatory affairs work.
How Brazil's ANVISA modernization is reshaping registration pathways, reliance mechanisms, and hiring demand for regulatory affairs professionals working on Latin America.
Breakthrough Therapy Designation brings intensive FDA guidance and rolling review, not a lower evidence bar. What it actually changes for regulatory affairs work.
The EU's proposed pharmaceutical legislation overhaul could reshape exclusivity, timelines, and labeling. Here's what it means for regulatory affairs work.
